Stock data
ImmunityBio, Inc. (IBRX)
ImmunityBio, Inc. (IBRX) reported revenue of US$113.29M and net income of -US$351.40M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$113.29M | — | -US$256.03M | -US$351.40M | — |
| 2024 | US$14.74M | — | -US$344.18M | -US$413.56M | — |
| 2023 | US$0.62M | — | -US$362.25M | -US$583.20M | — |
| 2022 | US$0.24M | — | -US$351.30M | -US$416.57M | — |
| 2021 | US$0.93M | — | -US$330.28M | -US$346.79M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$51.24M | -US$230.38M | — |
| 2026-03-31 | US$44.21M | -US$632.78M | — |
| 2025-12-31 | US$38.28M | -US$61.94M | — |
| 2025-09-30 | US$32.06M | -US$67.25M | — |
| 2025-06-30 | US$26.43M | -US$92.56M | — |
| 2025-03-31 | US$16.52M | -US$129.65M | — |
| 2024-12-31 | US$7.55M | -US$59.16M | — |
| 2024-09-30 | US$6.11M | -US$85.73M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.